Sign In
Buy RXRX
$3.52
+0.180 (+5.39%)
At Close: Jun 26, 2026
SALT LAKE CITY, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, today announced that the first patient
Prediction: These 2 Stocks Could Soar in 2025
09:45am, Thursday, 17'th Oct 2024
The key word here is "could."
Cathie Wood Is Betting on This AI Stock: Is It a Buy?
10:15am, Tuesday, 15'th Oct 2024
Wood has a stake in this stock, but it's hardly an "all-in" bet.
Down 57% in 2024, Is Recursion Pharmaceuticals a Buy on the Dip?
05:51am, Tuesday, 15'th Oct 2024
This clinical-stage drugmaker's AI platform could speed up the development process, but initial results were disappointing.
SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Investigates the Mergers and Imminent Votes of RXRX and EXAI
04:30pm, Friday, 11'th Oct 2024
NEW YORK, NY / ACCESSWIRE / October 11, 2024 / Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Se
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
10:15am, Tuesday, 08'th Oct 2024
The popular growth investor keeps adding to some of her favorite falling stocks.
2 Artificial Intelligence Stocks That Could Deliver Explosive Gains
06:45am, Monday, 07'th Oct 2024
These two AI innovators are reshaping drug discovery and voice technology – find out why Wall Street sees major upside ahead.
Recursion Pharmaceuticals (RXRX) Stock Dips While Market Gains: Key Facts
06:56pm, Wednesday, 02'nd Oct 2024
Recursion Pharmaceuticals (RXRX) concluded the recent trading session at $6.11, signifying a -0.97% move from its prior day's close.
Recursion gets FDA approval to begin phase 1 trials of AI-discovered cancer treatment
08:32am, Wednesday, 02'nd Oct 2024
Recursion said it was able to use its AI-enabled drug discovery platform to identify a novel target and move all the way to gaining IND approval in less than 18 months.
SALT LAKE CITY, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced that the U.S. Foo
2 Innovative Cathie Wood Stocks to Buy If You Can Stomach the Risk
05:44am, Sunday, 29'th Sep 2024
Cathie Wood invests in businesses that are risky, but with a lot of upside. Intellia Therapeutics has a couple of key readouts coming up.
Recursion Pharmaceuticals (RXRX) Stock Dips While Market Gains: Key Facts
06:56pm, Monday, 23'rd Sep 2024
In the most recent trading session, Recursion Pharmaceuticals (RXRX) closed at $6.67, indicating a -1.91% shift from the previous trading day.
Is Recursion Pharmaceuticals Stock a Buy?
08:30am, Friday, 20'th Sep 2024
Recursion Pharmaceuticals has an exciting approach to developing therapies. The company recently reported positive phase 2 results for one of its products.
ANGLE signs pilot study agreement with AI-powered Recursion Pharmaceuticals
02:51am, Thursday, 19'th Sep 2024
ANGLE PLC (AIM:AGL, OTCQX:ANPCY) shared further positive news with investors on Thursday, revealing it has signed an agreement with Nasdaq-listed Recursion Pharmaceuticals Inc for a fully funded pilo
Cathie Wood's Stock Shuffle: 1 Stock She's Loving, 1 She's Leaving
08:01am, Saturday, 07'th Sep 2024
Investors either love Cathie Wood or hate her. The founder of the Ark Invest family of exchange-traded funds can either be phenomenally successful or a dismal failure.
